Sev­er­al CEOs and 17 years lat­er, Melin­ta scores an FDA OK for its an­tibi­ot­ic

 

It’s tak­en 17 years and a long chain of CEOs, but pri­vate­ly held Melin­ta Ther­a­peu­tics has nabbed an FDA ap­proval for its an­tibi­ot­ic de­lafloxacin, which can now be sold as Baxdela.

Melin­ta an­nounced a lit­tle more than a year ago that the an­tibi­ot­ic had proven non-in­fe­ri­or to van­comycin for acute bac­te­r­i­al skin and skin struc­ture in­fec­tions (AB­SS­SI). The last switch up in the ex­ec­u­tive suite at Melin­ta, once called Rib-X, was when Mary Szela— now CEO of Nov­e­l­ion — was re­placed by R&D chief Eu­gene Sun in 2015.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.